Flores GMA

Language: Spanish
References: 11
Page: 379-382
PDF size: 554.59 Kb.

ABSTRACT

Introduction: obesity is one of the most important risk factors linked to the increase in cardiovascular diseases, type II diabetes, hypertension, arthritis, and some types of cancer. Furthermore, it is considered the most prevalent non-communicable disease in the world. In recent decades, obesity and overweight have become a public health problem that is increasing every day, both in developed and developing countries. Following this trend, in Mexico, the 2022 National Health and Nutrition Survey (ENSANUT 2022) showed that the prevalence of obesity was 41.0% in women and 32.3% in men. These data reaffirm that obesity is a critical health problem in Mexico, with a high prevalence and association with multiple comorbidities. Objective: to compare the efficacy of semaglutide versus dietary hygiene interventions in reducing body weight at three months. Material and methods: a retrospective study was carried out in 66 overweight or obese patients, comparing weight loss in two groups: semaglutide vs. diet-exercise. Results: the semaglutide group lost significantly more weight (12.7 ± 5.9 kg) than the non-pharmacological group (5.1 ± 2.9 kg), p < 0.000001. Conclusion: semaglutide has shown greater efficacy than non-pharmacological intervention in the Mexican population in the short term.

REFERENCES

1. World Health Organization. Notas descriptivas. Obesidad ysobrepeso. WHO, 2024. Disponible en: https://www.who.int/newsroom/fact-sheets/detail/obesity-and-overweight

2. Organisation for Economic Co-operation and Development.The heavy burden of obesity: the economics of prevention.OECD Health Policy Studies. Paris: OECD Publishing; 2019. doi:10.1787/67450d67-en

3. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Navarro-Olivos E, Bautista-Arredondo S et al. EncuestaNacional de Salud y Nutrición 2021 sobre Covid-19. Resultadosde Guanajuato. Cuernavaca, México: Instituto Nacional de SaludPública; 2022.

4. Barquera S, Rivera JA. Obesity in Mexico: rapid epidemiologicaltransition and food industry interference in health policies. LancetDiabetes Endocrinol. 2020; 8 (9): 746-747. doi: 10.1016/s2213-8587(20)30269-2.

5. Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JEet al. Worldwide trends in underweight and obesity from 1990 to2022: a pooled analysis of 3663 population-representative studieswith 222 million children, adolescents, and adults. Lancet. 2024;403 (10431): 1027-1050. doi: 10.1016/s0140-6736(23)02750-2.

6. Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modificationfor obesity: New developments in diet, physical activity, and behaviortherapy. Circulation. 2012; 125 (9): 1157-1170. doi: 10.1161/circulationaha.111.039453.

7. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF,Lingvay I et al. Efficacy and safety of once-weekly subcutaneoussemaglutide 2.4 MG in adults with overweight or obesity (STEP 1).J Endocr Soc. 2021; 5 (Supplement_1): A10. doi: 10.1210/jendso/bvab048.018.

8. Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD,Perreault L, et al. Semaglutide 2.4 mg once a week in adults withoverweight or obesity, and type 2 diabetes (STEP 2) : a randomised,double blind, double-dummy, placebo-controlled, phase 3 trial.Lancet. 2021; 397 (10278): 971-984. doi: 10.1016/S0140-6736(21) 00213-0.

9. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, JensenC et al. Effect of continued weekly subcutaneous semaglutide vsplacebo on weight loss maintenance in adults with overweight orobesity: the STEP 4 randomized clinical trial. JAMA. 2021; 325 (14):1414–1425. doi: 10.1001/jama.2021.3224.

10. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, JastreboffAM, et al. American Association of Clinical Endocrinologists andAmerican College of Endocrinology comprehensive clinical practiceguidelines for medical care of patients with obesity. Endocr Pract.2016; 22 (Suppl 3): 1-203. doi: 10.4158/EP161365.GL.

11. Drucker DJ. GLP-1 physiology informs the pharmacotherapyof obesity. Mol Metab. 2022; (57): 101351. doi: 10.1016/j.molmet.2021.101351.